

4/16/04

PATENT
Attorney Docket No.: MEDIV2010-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Epstein et al. Art Unit: 1632
Application No.: 10/618,183 Examiner: Not Yet Assigned
Filing Date: July 10, 2003 Confirmation No.: 4304
Title: INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM
FOR ANGIOGENESIS


MAIL STOP 1632
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application please find:

1. Information Disclosure Statement (2 pgs.);
2. Form PTO-1449 (2 pgs. in duplicate); and
3. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, April 6, 2004, in an envelope addressed to: MAIL STOP 1632, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	April 6, 2004 (Date)


In re Application of:
Epstein et al.
Application No.: 10/618,183
Filed: July 10, 2003
Page 2

PATENT
Attorney Docket No.: MEDIV2010-4

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: April 6, 2004



June M. Learn, J.D., Ph.D.

Registration No. 31,238

Telephone: (858) 677-1416

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO CUSTOMER NO. 28213

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Epstein et al. Art Unit: 1632
Application No.: 10/618,183 Examiner: Not Yet Assigned
Filing Date: July 10, 2003 Confirmation No.: 4304
Title: INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM
FOR ANGIOGENESIS

MAIL STOP 1632
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COPY

TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application please find:

1. Information Disclosure Statement (2 pgs.);
2. Form PTO-1449 (2 pgs. in duplicate); and
3. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, April 6, 2004 , in an envelope addressed to: MAIL STOP 1632, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Gregory P. Austin</u> (Name of Person Mailing Paper)	
<u>Gregory P. Austin</u> (Signature)	<u>April 6, 2004</u> (Date)

In re Application of:

Epstein et al.

Application No.: 10/618,183

Filed: July 10, 2003

Page 2


PATENT

Attorney Docket No.: MEDIV2010-4

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: April 6, 2004



June M. Learn, J.D., Ph.D.

Registration No. 31,238

Telephone: (858) 677-1416

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP

4365 Executive Drive, Suite 1100

San Diego, California 92121-2133

USPTO CUSTOMER NO. 28213

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Epstein et al. Art Unit: 1632
Application No.: 10/618,183 Examiner: Not Yet Assigned
Filing Date: July 10, 2003 Confirmation No.: 4304
Title: INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM
FOR ANGIOGENESIS


MAIL STOP 1632
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, Applicants bring the references listed on the attached Form PTO-1449 to the attention of the Examiner for the above-identified application. Copies of the references will be found in prior application, U.S. Serial No. 09/868,411, filed June 14, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

It is respectfully requested that the references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, April 6, 2004 , in an envelope addressed to: MAIL STOP 1632, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	April 6, 2004 (Date)


In re Application of:
Epstein et al.
Application No.: 10/618,183
Filed: July 10, 2003
Page 2

PATENT
Attorney Docket No.: MEDIV2010-4

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed prior to the mailing of a first office action on the merits of the above-identified application. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: April 6, 2004


June M. Learn, J.D., Ph.D.
Registration No. 31,238
Telephone: (858) 677-1416
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO CUSTOMER NO. 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: MEDIV2010-4	Application No.: 10/618,183
	Applicant: Epstein et al.	Confirmation No.: 4304
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: July 10, 2003	Group Art Unit: 1632

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

		Anderson, "Human gene therapy", <i>Nature</i> , 392(6679 Supp.):25-30 (April 1998)
		Bickenbach et al., "Selection and Extended Growth of Murine Epidermal Stem Cells in Culture", <i>Exp. Cell Res.</i> , 244(1):184-195 (Oct. 1998)
		Blanquaert et al., "RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration", <i>J. Biomed. Mater. Res.</i> , 64A(3):525-532 (March 2003)
		Blume et al., "A Review of Autologous Hematopoietic Cell Transplantation", <i>Biology of Blood and Marrow Transplantation</i> , 6:1-12 (2000)
		Brugger al., "Ex Vivo Manipulation of Hematopoietic Stem and Progenitor Cells", <i>Seminars in Hematology</i> , 37(1)(Supplement 2):42-49 (Jan. 2000)
		Check, "Cancer fears cast doubts on future of gene therapy", <i>Nature</i> , 421(6924):678 (Feb. 2003)
		Dini et al., "Peripheral Blood Stem Cell Collection from G-CSF-Stimulated Unrelated Donors for Second Transplant," <i>Bone Marrow Transplantation</i> , 22(Supplement 5):S41-S45 (1998)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: MEDIV2010-4	Application No.: 10/618,183
	Applicant: Epstein et al.	Confirmation No.: 4304
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: July 10, 2003	Group Art Unit: 1632

	Fielding et al., "Autologous Bone Marrow Transplantation", <i>Current Opinion in Hematology</i> , 1:412-417 (1994)
	Kanj et al., "Myocardial Ischemia Associated With High-Dose Carmustine Infusion," <i>Cancer</i> , 68:1910-1912 (Nov. 1991)
	Juengst, "What next for human gene therapy?", <i>BMJ</i> , 326(7404):1410-1411 (June 2003)
	Kmieciak, "Gene Therapy", <i>American Scientist</i> , 87:240-247 (May-June 1999)
	Noishiki et al., "Angiogenic Growth Factor Release System for In Vivo Tissue Engineering: A Trial of Bone Marrow Transplantation into Ischemic Myocardium," <i>J. Artif. Organs</i> , 2:85-91 (1999)
	Perin et al., "Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure", <i>Circulation</i> , 107(18):2294-2302 (May 2003)
	Simnett et al., "Autologous Stem Cell Transplantation for Malignancy: A Systematic Review of the Literature," <i>Clin. Lab. Haem.</i> , 22:61-72 (2000)
	Stamm et al., "Autologous bone-marrow stem-cell transplantation for myocardial regeneration", <i>The Lancet</i> , 361(9351):45-46 (Jan. 2003)
	Tao et al., "Evidence for transdifferentiation of human bone marrow-derived stem cells: recent progress and controversies", <i>Pathology</i> , 35(1):6-13 (Feb. 2003)
	Tomita et al., "Autologous Transplantation of Bone Marrow Cells Improves Damaged Heart Function", <i>Circulation</i> , 100(19 Suppl):II247-II256 (Nov. 1999)
	Vaughan et al., "Roundtable Discussion: Incorporating Bone Marrow Transplantation Into NCCN Guidelines," <i>Oncotherapy</i> , 12(11A):390-392, NCCN Proceedings (Nov. 1998)
	Verma et al., "Gene therapy - promises, problems and prospects", <i>Nature</i> , 389(6648):239-42 (Sept. 1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: MEDIV2010-4	Application No.: 10/618,183
	Applicant: Epstein et al.	Confirmation No.: 4304
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: July 10, 2003	Group Art Unit: 1632

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Anderson, "Human gene therapy", <i>Nature</i> , 392(6679 Supp.):25-30 (April 1998)
	Bickenbach et al., "Selection and Extended Growth of Murine Epidermal Stem Cells in Culture", <i>Exp. Cell Res.</i> , 244(1):184-195 (Oct. 1998)
	Blanquaert et al., "RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration", <i>J. Biomed. Mater. Res.</i> , 64A(3):525-532 (March 2003)
	Blume et al., "A Review of Autologous Hematopoietic Cell Transplantation", <i>Biology of Blood and Marrow Transplantation</i> , 6:1-12 (2000)
	Brugger al., "Ex Vivo Manipulation of Hematopoietic Stem and Progenitor Cells", <i>Seminars in Hematology</i> , 37(1)(Supplement 2):42-49 (Jan. 2000)
	Check, "Cancer fears cast doubts on future of gene therapy", <i>Nature</i> , 421(6924):678 (Feb. 2003)
	Dini et al., "Peripheral Blood Stem Cell Collection from G-CSF-Stimulated Unrelated Donors for Second Transplant," <i>Bone Marrow Transplantation</i> , 22(Supplement 5):S41-S45 (1998)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: MEDIV2010-4	Application No.: 10/618,183
	Applicant: Epstein et al.	Confirmation No.: 4304
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: July 10, 2003	Group Art Unit: 1632

	Fielding et al., "Autologous Bone Marrow Transplantation", <i>Current Opinion in Hematology</i> , 1:412-417 (1994)
	Kanj et al., "Myocardial Ischemia Associated With High-Dose Carmustine Infusion," <i>Cancer</i> , 68:1910-1912 (Nov. 1991)
	Juengst, "What next for human gene therapy?", <i>BMJ</i> , 326(7404):1410-1411 (June 2003)
	Kmiec, "Gene Therapy", <i>American Scientist</i> , 87:240-247 (May-June 1999)
	Noishiki et al., "Angiogenic Growth Factor Release System for In Vivo Tissue Engineering: A Trial of Bone Marrow Transplantation into Ischemic Myocardium," <i>J. Artif. Organs</i> , 2:85-91 (1999)
	Perin et al., "Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure", <i>Circulation</i> , 107(18):2294-2302 (May 2003)
	Simnett et al., "Autologous Stem Cell Transplantation for Malignancy: A Systematic Review of the Literature," <i>Clin. Lab. Haem.</i> , 22:61-72 (2000)
	Stamm et al., "Autologous bone-marrow stem-cell transplantation for myocardial regeneration", <i>The Lancet</i> , 361(9351):45-46 (Jan. 2003)
	Tao et al., "Evidence for transdifferentiation of human bone marrow-derived stem cells: recent progress and controversies", <i>Pathology</i> , 35(1):6-13 (Feb. 2003)
	Tomita et al., "Autologous Transplantation of Bone Marrow Cells Improves Damaged Heart Function", <i>Circulation</i> , 100(19 Suppl):II247-II256 (Nov. 1999)
	Vaughan et al., "Roundtable Discussion: Incorporating Bone Marow Transplantation Into NCCN Guidelines," <i>Onocology</i> , 12(11A):390-392, NCCN Proceedings (Nov. 1998)
	Verma et al., "Gene therapy - promises, problems and prospects", <i>Nature</i> , 389(6648):239-42 (Sept. 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw e through citation if not in conformance and not considered. Include copy of this form with next nmunication to applicant.

m 1449